Logo image of AIMD

AINOS INC (AIMD) Stock Fundamental Analysis

NASDAQ:AIMD - Nasdaq - US00902F3038 - Common Stock - Currency: USD

0.6321  -0.03 (-4.23%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AIMD. AIMD was compared to 571 industry peers in the Biotechnology industry. AIMD has a bad profitability rating. Also its financial health evaluation is rather negative. AIMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AIMD had negative earnings in the past year.
AIMD had a negative operating cash flow in the past year.
AIMD had negative earnings in each of the past 5 years.
In the past 5 years AIMD always reported negative operating cash flow.
AIMD Yearly Net Income VS EBIT VS OCF VS FCFAIMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M

1.2 Ratios

AIMD has a Return On Assets (-51.43%) which is in line with its industry peers.
AIMD has a Return On Equity of -89.52%. This is comparable to the rest of the industry: AIMD outperforms 49.02% of its industry peers.
Industry RankSector Rank
ROA -51.43%
ROE -89.52%
ROIC N/A
ROA(3y)-30.18%
ROA(5y)-182.31%
ROE(3y)-44.97%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIMD Yearly ROA, ROE, ROICAIMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K 2K

1.3 Margins

AIMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIMD Yearly Profit, Operating, Gross MarginsAIMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

AIMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIMD has been reduced compared to 1 year ago.
The number of shares outstanding for AIMD has been increased compared to 5 years ago.
AIMD has a worse debt/assets ratio than last year.
AIMD Yearly Shares OutstandingAIMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
AIMD Yearly Total Debt VS Total AssetsAIMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -3.26, we must say that AIMD is in the distress zone and has some risk of bankruptcy.
AIMD has a Altman-Z score (-3.26) which is comparable to the rest of the industry.
AIMD has a Debt/Equity ratio of 0.51. This is a neutral value indicating AIMD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.51, AIMD is doing worse than 75.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z -3.26
ROIC/WACCN/A
WACC8.03%
AIMD Yearly LT Debt VS Equity VS FCFAIMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M 30M

2.3 Liquidity

AIMD has a Current Ratio of 1.37. This is a normal value and indicates that AIMD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.37, AIMD is doing worse than 83.48% of the companies in the same industry.
AIMD has a Quick Ratio of 1.33. This is a normal value and indicates that AIMD is financially healthy and should not expect problems in meeting its short term obligations.
AIMD's Quick ratio of 1.33 is on the low side compared to the rest of the industry. AIMD is outperformed by 83.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.33
AIMD Yearly Current Assets VS Current LiabilitesAIMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AIMD have decreased strongly by -442.44% in the last year.
Looking at the last year, AIMD shows a very negative growth in Revenue. The Revenue has decreased by -96.44% in the last year.
Measured over the past years, AIMD shows a quite strong growth in Revenue. The Revenue has been growing by 8.83% on average per year.
EPS 1Y (TTM)-442.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.65%
Revenue 1Y (TTM)-96.44%
Revenue growth 3Y82.77%
Revenue growth 5Y8.83%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AIMD Yearly Revenue VS EstimatesAIMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
AIMD Yearly EPS VS EstimatesAIMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AIMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIMD Price Earnings VS Forward Price EarningsAIMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIMD Per share dataAIMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AIMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AINOS INC

NASDAQ:AIMD (2/20/2025, 8:00:00 PM)

0.6321

-0.03 (-4.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-06 2025-03-06
Inst Owners1.11%
Inst Owner Change-58.87%
Ins Owners11.31%
Ins Owner Change3.1%
Market Cap8.75M
AnalystsN/A
Price TargetN/A
Short Float %9.81%
Short Ratio0.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 215.32
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.77
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0
BVpS1.3
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.43%
ROE -89.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.18%
ROA(5y)-182.31%
ROE(3y)-44.97%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.07%
Cap/Sales 8.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.33
Altman-Z -3.26
F-Score1
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)7.27%
Cap/Depr(5y)34.36%
Cap/Sales(3y)39.26%
Cap/Sales(5y)53.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-442.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.65%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.44%
Revenue growth 3Y82.77%
Revenue growth 5Y8.83%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.83%
OCF growth 3YN/A
OCF growth 5YN/A